Kalaris Therapeutics, Inc. (KLRS)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
Key ratios (FY2025)
-55.1%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $165.0K | — |
| Operating Income | -$46.15M | -$51.73M | -$199.90M | -$171.20M | -$169.82M | -$71.31M | -$26.70M | — |
| Net Income | -$43.44M | -$69.17M | -$190.42M | -$168.71M | -$171.96M | -$69.78M | -$23.84M | — |
| EPS (Diluted) | $-2.85 | $-51.77 | $-42.09 | $-2.20 | $-2.74 | — | — | — |
| Total Assets | $121.74M | $6.16M | $190.80M | $277.08M | $286.59M | $370.82M | $139.42M | — |
| Total Liabilities | $42.92M | $56.78M | $45.02M | $52.56M | $61.33M | $17.76M | $17.80M | — |
| Shareholders' Equity | $78.81M | -$96.62M | -$45.02M | $224.52M | $225.27M | $353.06M | -$51.50M | -$30.62M |
| Cash & Equivalents | $98.05M | $1.64M | $90.12M | $106.09M | $201.66M | $122.66M | $61.08M | — |
| Operating Cash Flow | -$38.37M | -$20.67M | -$124.45M | -$142.05M | -$106.32M | -$60.81M | -$20.16M | — |
| Capital Expenditures | $200.0K | — | — | — | $26.0K | $235.0K | $339.0K | — |
| Shares Outstanding | 22.90M | 1.36M | 4.96M | 93.09M | 63.57M | 61.93M | 2.10M | — |